Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, TX
Treatments:Biologic therapyHospital:The University of Texas MD Anderson Cancer Center
Drugs:Journal:Link
Date:Jan 2012

Description:

Patients:
This phase II study involved 45 women with metastatic breast cancer who had received prior chemotherapy. The median age was 50 years.

Treatment:
Patients were treated with the biologic therapy agent R11.4610 (also known as Angiozyme), which is an enzyme that stops the VEGFR protein (involved in tumor growth) from being made.

Toxicities:
There was one case of grade 4 jaundice, which was the most severe adverse event reported. Nerve disorders and pain were also reported.

Results:
The reported median overall survival was 11.89 months.

Support:
This study was supported by Sirna Therapeutics, the makers of Angiozyme.

Correspondence: Dr. Phuong Khanh H. Morrow; email: [email protected]



Back